Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease
Pitching Euclidean Capital? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room